Glaucoma Overview

Glaucoma Overview

Glaucoma refers to a group of eye disorders that result in damage to the optic nerve, commonly caused by elevated intraocular pressure. If not properly managed, this pressure buildup can lead to gradual and irreversible vision loss. Because it often develops silently and without pain, many individuals remain unaware of vision changes until the disease has progressed significantly.

The most widespread form is primary open-angle glaucoma. Several risk factors contribute to the development of glaucoma, including aging, family history, and underlying health issues such as diabetes. Regular eye exams are essential for early detection. While there is no cure, treatments like medicated eye drops, oral medications, and surgical procedures can help lower eye pressure and slow disease progression.

Understanding starts here—check out the infographic for key insights : 

https://www.delveinsight.com/infographics/glaucoma-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Glaucoma Epidemiological Segmentation (2020–2034, 7MM)

• Total Prevalent Cases

• Total Diagnosed Prevalent Cases

• Diagnosed Cases by Glaucoma Type (including Open-Angle Glaucoma)

• Gender-specific Diagnosed Cases

• Age-specific Diagnosed Cases
  
  

Epidemiology Highlights

• In 2023, the United States accounted for about 35% of all diagnosed glaucoma cases in the 7MM.

• Japan made up approximately 22% of the diagnosed population.

• The EU4 and the UK contributed to around 43% of the total diagnosed cases in the 7MM.

• Diagnosed cases were slightly more prevalent among females (54%) compared to males (46%) in 2023.
  
  

From snapshot to strategy—unlock the full report : 

https://www.delveinsight.com/report-store/glaucoma-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Glaucoma Market Overview

The glaucoma market across the 7MM was valued at around USD 1.6 billion in 2023.

Market Growth Drivers

• Increasing global burden of glaucoma spurring demand for better diagnostic tools and treatments.

• Technological innovations supporting early disease detection and efficient monitoring.

• Collaborative healthcare approaches enhancing comprehensive disease management.

• Public health initiatives and awareness campaigns promoting early diagnosis and treatment adherence.
  
  

Market Barriers

• Many patients struggle with maintaining consistent, lifelong treatment routines.

• Access to advanced care remains limited in resource-constrained regions.

• High costs associated with newer therapies and surgical interventions.

• Poor adherence to prescribed therapies reduces their long-term effectiveness.
  
  

Get the facts at a glance—view our new infographic : Click Here

Emerging Therapies in Glaucoma

Promising new treatments in development include:

• NCX-470

• PDP-716

• Sepetaprost (ONO-9054 / DE-126 / STN-1012600)

• TRS01

• And others
  
  

Key Companies in the Glaucoma Market

Leading players actively involved in glaucoma drug development and commercialization:

• Nicox Ophthalmics

• Sun Pharma Advanced Research Company Limited (SPARC) / Visiox Pharma

• Santen Pharmaceutical

• Tarsier Pharma

• And others

Act on data, not guesses—download the full report now : Get it now